Literature DB >> 24056375

Hunter syndrome (Mucopolysaccharidosis type II), severe phenotype: long term follow-up on patients undergone to hematopoietic stem cell transplantation.

R Annibali1, L Caponi, A Morganti, M Manna, O Gabrielli, A Ficcadenti.   

Abstract

AIM: Our study aim is the evaluation of long-term effects of hematopoietic stem cell transplantation on Italian patients with severe Hunter syndrome.
METHODS: Four boys, suffering from Hunter syndrome, severe phenotype, received hematopoietic stem cell transplantation between 2 years 6 months and 2 years 11 months of age, from 1992 to 2001. A complete multidisciplinary evaluation of hematopoietic stem cell transplantation long-term effects was performed periodically.
RESULTS: All patients achieved successful engraftment. Urine glycosaminoglycans excretion was reduced or normalized, and the activity of leukocyte iduronate-2-sulphatase enzyme, absent before hematopoietic stem cell transplantation, remained constant, in all patients. Dysostosis multiplex progressed over time, according to the natural evolution of the disease. Joint stiffness improved in all affected districts. Hepatosplenomegaly decreased until it disappeared. The cardiovascular involvement stayed unchanged, as well as hearing loss. Skin became hyperelastical; face features seemed less coarse if compared to the natural evolution of the disease. Cerebral white matter alterations were constant in time. On the contrary, the hematopoietic stem cell transplantation did not prove to have long-term effectiveness on neurological symptoms of Hunter syndrome.
CONCLUSION: The hematopoietic stem cell transplantation was successful in slowing the progression of Hunter syndrome, and even the evolution of neurological feature of the disease was slower in the first years after this treatment.

Entities:  

Mesh:

Year:  2013        PMID: 24056375

Source DB:  PubMed          Journal:  Minerva Pediatr        ISSN: 0026-4946            Impact factor:   1.312


  7 in total

Review 1.  Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?

Authors:  Claire Horgan; Simon A Jones; Brian W Bigger; Robert Wynn
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

Review 2.  Recent trends in mucopolysaccharidosis research.

Authors:  Hiroshi Kobayashi
Journal:  J Hum Genet       Date:  2018-11-19       Impact factor: 3.172

3.  Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II.

Authors:  Francyne Kubaski; Hiromasa Yabe; Yasuyuki Suzuki; Toshiyuki Seto; Takashi Hamazaki; Robert W Mason; Li Xie; Tor Gunnar Hugo Onsten; Sandra Leistner-Segal; Roberto Giugliani; Vũ Chí Dũng; Can Thi Bich Ngoc; Seiji Yamaguchi; Adriana M Montaño; Kenji E Orii; Toshiyuki Fukao; Haruo Shintaku; Tadao Orii; Shunji Tomatsu
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-01       Impact factor: 5.742

Review 4.  Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism.

Authors:  Jessica M Sun; Joanne Kurtzberg
Journal:  Pediatr Res       Date:  2017-11-08       Impact factor: 3.756

Review 5.  Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review.

Authors:  Linda A Bradley; Hamish R M Haddow; Glenn E Palomaki
Journal:  Genet Med       Date:  2017-05-18       Impact factor: 8.822

6.  Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome.

Authors:  Daniel C Julien; Kara Woolgar; Laura Pollard; Holly Miller; Ankit Desai; Kristin Lindstrom; Priya S Kishnani
Journal:  Front Immunol       Date:  2020-05-21       Impact factor: 7.561

7.  Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).

Authors:  Molly Stapleton; Francyne Kubaski; Robert W Mason; Hiromasa Yabe; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2017-03-08       Impact factor: 0.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.